Treatment strategies for chronic hepatitis C prior to and following liver transplantation

World Journal of Hepatology

Volumn 8, Issue 1, 2016, Pages 69-73

  Perumpail, Ryan B ^a   Hahambis, Thomas A ^b   Aggarwal, Avin ^a   Younossi, Zobair M ^c,d   Ahmed, Aijaz ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GILEAD SCIENCES   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

^d BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

Direct acting antivirals; Hepatitis C virus; Liver transplantation; Sustained virologic response

Indexed keywords

EID: 84953889428     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v8.i1.69     Document Type: Article

References (36)

1. Wray CM, Davis AM. Screening for hepatitis C. JAMA 2015;313:1855-1856 [PMID: 25965235 DOI: 10.1001/jama.2015.2833]
2. Chung RT, Baumert TF. Curing chronic hepatitis C--the arc of a medical triumph. N Engl J Med 2014;370:1576-1578 [PMID: 24720678 DOI: 10.1056/NEJMp1400986]
3. Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:349-357 [PMID: 23798026 DOI: 10.7326/0003-4819-159-5-201309030-00672]
4. Dhanasekaran R, Sanchez W, Mounajjed T, Wiesner RH, Watt KD, Charlton MR. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int 2015;35:2433-2441 [PMID: 26058570 DOI: 10.1111/liv.12890]
5. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466 [PMID: 7739682 DOI: 10.1056/NEJM199506013322202]
6. Brechot C, Nalpas B, Feitelson MA. Interactions between alcohol and hepatitis viruses in the liver. Clin Lab Med 1996;16:273-287 [PMID: 8792072]
7. Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998;28:562-567 [PMID: 9696025 DOI: 10.1002/hep.510280238]
8. Marrone A, Sallie R. Genetic heterogeneity of hepatitis C virus. The clinical significance of genotypes and quasispecies behavior. Clin Lab Med 1996;16:429-449 [PMID: 8792081]
9. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The O.B.svirc, metavir, clinivir, and dosvirc groups. Lancet 1997;349:825-832 [PMID: 9121257 DOI: 10.1016/S0140-6736(96)07642-8]
10. Simmonds P. Variability of hepatitis C virus. Hepatology 1995;21:570-583 [PMID: 7531173 DOI: 10.1002/hep.1840210243]
11. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm S.W, Realdi G. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472 [PMID: 9024300 DOI: 10.1053/gast.1997.v112.pm9024300]
12. Serfaty L, Aumaître H, Chazouillères O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-1440 [PMID: 9581703 DOI: 10.1002/hep.510270535]
13. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-684 [PMID: 18025443 DOI: 10.7326/0003-4819-147-10-200711200-00003]
14. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593 [PMID: 23268517 DOI: 10.1001/jama.2012.144878]
15. van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE, Janssen HL. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 2014;312:1927-1928 [PMID: 25387192 DOI: 10.1001/jama.2014.12627]
16. Fortune BE, Martinez-Camacho A, Kreidler S, Gralla J, Everson GT. Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. Transpl Int 2015;28:980-989 [PMID: 25818896 DOI: 10.1111/tri.12568]
17. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896 [PMID: 11910340 DOI: 10.1053/gast.2002.32418]
18. Charpentier KP, Mavanur A. Removing patients from the liver transplant wait list: A survey of US liver transplant programs. Liver Transpl 2008;14:303-307 [PMID: 18306339 DOI: 10.1002/lt.21353]
19. Gentry SE, Massie AB, Cheek SW, Lentine KL, Chow EH, Wickliffe CE, Dzebashvili N, Salvalaggio PR, Schnitzler MA, Axelrod DA, Segev D.L. Addressing geographic disparities in liver transplantation through redistricting. Am J Transplant 2013;13:2052-2058 [PMID: 23837931 DOI: 10.1111/ajt.12301]
20. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-893 [PMID: 20683932 DOI: 10.1002/hep.23785]
21. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian G.M, McHutchison J.G, Heathcote E.J. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-475 [PMID: 23234725 DOI: 10.1016/S0140-6736(12)61425-1]
22. Ferrell LD, Wright TL, Roberts J, Ascher N, Lake J. Hepatitis C viral infection in liver transplant recipients. Hepatology 1992;16:865-876 [PMID: 1383115 DOI: 10.1002/hep.1840160403]
23. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, Maertens G, Williams R. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820 [PMID: 8596547 DOI: 10.1056/NEJM199603283341302]
24. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96 [PMID: 12512033 DOI: 10.1053/gast.2003.50016]
25. Åberg F, Nordin A, Mäkisalo H, Isoniemi H. Who is too healthy and who is too sick for liver transplantation: external validation of prognostic scores and survival-benefit estimation. Scand J Gastroenterol 2015;50:1144-1151 [PMID: 25865580 DOI: 10.3109/00365521.2015.1028992]
26. Bonacci M, Londoño M.C, Esforzado N, Forns X, Sotoca JM, Campistol JM. Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list. Transpl Int 2015;28:1345-1349 [PMID: 26073850 DOI: 10.1111/tri.12622]
27. Massie AB, Caffo B, Gentry SE, Hall EC, Axelrod DA, Lentine KL, Schnitzler MA, Gheorghian A, Salvalaggio PR, Segev DL. MELD Exceptions and Rates of Waiting List Outcomes. Am J Transplant 2011;11:2362-2371 [PMID: 21920019 DOI: 10.1111/j.1600-6143.2011.03735.x]
28. Massie AB, Chow EK, Wickliffe CE, Luo X, Gentry SE, Mulligan DC, Segev DL. Early changes in liver distribution following implementation of Share 35. Am J Transplant 2015;15:659-667 [PMID: 25693474 DOI: 10.1111/ajt.13099]
29. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, Brandt-Sarif T, Chang P, Kivett V, Castells L, Prieto M, Fontana RJ, Baumert TF, Coilly A, Londoo MC, Habersetzer F. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015;61:1485-1494 [PMID: 25557906 DOI: 10.1002/hep.27681]
30. Charlton M, Gane E, Manns MP, Brown RS, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir AJ, McHutchison JG, Symonds WT, Brainard D, Kirby B, Dvory-Sobol H, Denning J, Arterburn S, Samuel D, Forns X, Terrault NA. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015;148:108-117 [PMID: 25304641 DOI: 10.1053/j.gastro.2014.10.001]
31. Patwardhan VR, Curry MP. Reappraisal of the hepatitis C viruspositive donor in solid organ transplantation. Curr Opin Organ Transplant 2015;20:267-275 [PMID: 25944236 DOI: 10.1097/MOT.0000000000000191]
32. Northup PG, Argo CK, Nguyen DT, McBride MA, Kumer SC, Schmitt TM, Pruett TL. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int 2010;23:1038-1044 [PMID: 20444239 DOI: 10.1111/j.1432-2277.2010.01092.x]
33. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Fried MW, Terrault NA, OLeary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 2015;149:649-659 [PMID: 25985734 DOI: 10.1053/j.gastro.2015.05.010]
34. Maor-Kendler Y, Batts KP, Burgart LJ, Wiesner RH, Krom RA, Rosen CB, Charlton MR. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation 2000;70:292-297 [PMID: 10933151 DOI: 10.1097/00007890-200007270-00009]
35. Sperl J, Petrasek J, Spicak J, Viklicky O. Acute rejection of nonfunctional allograft in kidney transplant recipients with hepatitis C treated with peginterferon-alpha 2a. J Hepatol 2008;49:461-462;author reply 462-463 [PMID: 18644649 DOI: 10.1016/j.jhep.2008.06.002]
36. Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, Markmann JF, Drazan KE, Holt C, Imagawa D, Goldstein LI, Martin P, Busuttil RW. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999;229:824-831;discussion 831-833 [PMID: 10363896 DOI: 10.1097/00000658-199906000-00009]